An open randomized study to compare narrow band UVB, topical @entity14429 and topical XXXX in the treatment of @entity1694 .

@entity1 @entity75 @entity1694 @entity14429 @entity1140
Vitiligo is an acquired loss of pigmentation and its treatment remains very difficult up to date. Narrow band ultraviolet B (NB-UVB) and topical immunomodulators are included among the most innovative @entity1694 . We evaluated the efficacy and tolerability of NB-UVB, topical @entity14429 and @entity1140 in the treatment of @entity1694 . Adult @entity1 with chronic and stable @entity1694 refractory to conventional therapies were enrolled in an open parallel groups study. The @entity1 were scheduled on the basis of a computer-generated randomization into three groups: 13 @entity1 received NB-UVB phototherapy 3 times a week, 15 @entity1 were treated with @entity14429 1% cream b.i.d. and 16 @entity1 applied @entity1140 0.1% ointment b.i.d. All three treatment regimens were performed for 24 weeks. At baseline and every three weeks for the whole period of therapy the @entity1 were examined through digital photographs and, at the end of the study, based on the percentage of repigmentation, treatment outcome was classified as "absent" (0), "slight" (< 25%), mild (25-49%), "moderate" (50-74%), and "excellent" (> 75%). During the whole period of the study, possible side effects were recorded. The response to treatments varied according to the anatomical location of the lesions. No statistically significant differences in repigmentation for any anatomical site were recorded with the three treatments. The best results were obtained for lesions of the face with @entity14429 cream and @entity1140 ointment and of the neck with NB-UVB. Statistically significant differences in repigmentation between photo-exposed and covered skin areas were recorded although the @entity1 were asked to avoid direct UV exposition and to apply a very high protection sun screen on @entity75 . All three treatments should be considered as a good option in the treatment of @entity1694 . NB-UVB irradiation may represent the optimal choice in generalized @entity1694 with topical immunomodulators in localized @entity1694 .
